Reported 8 months ago
FTNN News Network on June 19, 2024, reported that the biotech stock Medical Imaging (6637), newly listed on the OTC on the 18th at an offering price of 66 yuan per share, surged by 107% in 2 days. On the 19th, it rose by 32.5 yuan, closing at 137 yuan (+31.1%). Founded 32 years ago, Medical Imaging has never incurred losses, achieving a new high of EPS at 5.66 yuan in 2023. With a combined revenue of 330 million yuan from January to May this year, up 39.4% annually, and an EPS of 2.1 yuan in the first quarter, analysts are optimistic about its future profits. Chairman Xie Suihui stated at the listing ceremony that the company has long promoted preventive medicine and maintained close cooperation with global advanced medical device manufacturer GE, anticipating better performance this year. Newly listed pharmaceutical stock Clover-Bio (6617) also debuted on the 18th at an offering price of 141.16 yuan. However, due to delays in the introduction of the new drug PTS302 for treating severe lung cancer with central airway obstruction caused by Chinese anti-corruption policies, it dropped by 9% on the 2nd and fell by 3.5 yuan on the 19th, closing at 128.5 yuan (-2.65%).
Source: YAHOO